Establishment of a Mass-Spectrometry-Based Method for the Identification of the <i>In Vivo</i> Whole Blood and Plasma ADP-Ribosylomes

Blood and plasma proteins are heavily investigated as biomarkers for different diseases. However, the post-translational modification states of these rarely analyzed since blood contains many enzymes that rapidly remove modifications after sampling. In contrast to well-described role protein ADP-ribosylation in cells organs, its remains mostly uncharacterized. Here, we discovered phosphodiesterases and/or ADP-ribosylhydrolases demodify vitro ADP-ribosylated proteins. Thus, identify vivo whole ADP-ribosylomes, established a mass-spectrometry-based workflow was applied samples collected from LPS-treated pigs (Sus scrofa domesticus), which serves model human systemic inflammatory response syndrome. These analyses identified 60 proteins, 17 were This new protocol provides an important step forward developing field defines ADP-ribosylomes under both healthy disease conditions.